Reply to contradictory results with high-dosage rifamycin in mice and humans

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 1104-1105

  Nuermberger, Eric L ^a,b   Rosenthal, Ian M ^a   Tasneen, Rokeya ^a   Peloquin, Charles A ^c   Mdluli, Khisimuzi E ^d   Karakousis, Petros C ^a,b   Grosset, Jacques H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d Global Alliance for TB Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMYCIN; RIFAPENTINE;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL (TOPIC); DISEASE DURATION; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; HUMAN; LETTER; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; RELAPSE; SPUTUM; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 84872834713     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02216-12     Document Type: Letter

References (16)

1. Coates ARM, Hu Y, Jindani A, Mitchison DA. 2012. Contradictory results with high-dosage rifamycin in mice and humans. Antimicrob. Agent Chemother. 57:1103.
2. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. 2012. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 56:4331-4340.
3. Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW, Tuberculosis Trials Consortium. 2012. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: Study 29 of the Tuberculosis Trials Consortium. J. Infect. Dis. 206:1030-1040.
4. Mitchison DA. 2012. Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins. Int. J. Tuberc. Lung Dis. 16: 1186-1189.
5. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124.
6. Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL. 2006. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am. J. Respir. Crit. Care Med. 174:94-101.
7. Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, Grosset JH, Nuermberger EL. 2005. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 172:1457-1462.
8. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344. doi:10.1371/journal.pmed.0040344.
9. De Groote MA, Gilliland JC, Wells CL, Brooks EJ, Woolhiser LK, Gruppo V, Peloquin CA, Orme IM, Lenaerts AJ. 2011. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:1237-1247.
10. de Steenwinkel JE, ten Kate MT, de Knegt GJ, Verbrugh HA, van Belkum A, Hernandez-Pando R, Bakker-Woudenberg IA. 2011. Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size. Int. J. Tuberc. Lung Dis. 15:1478-1484.
11. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. 2009. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am. J. Respir. Crit. Care Med. 180:553-557.
12. Rosenthal IM, Zhang M, Grosset JH, Nuermberger EL. 2008. Rifapentine-containing regimens cure murine tuberculosis in weeks rather than months. Am. J. Respir. Crit. Care Med. 177:A789.
13. Hu Y, Mangan JA, Dhillon J, Sole KM, Mitchison DA, Butcher PD, Coates AR. 2000. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J. Bacteriol. 182:6358-6365.
14. Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Melia MT, Burman WJ, Dorman SE. 2012. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin. Pharmacol. Ther. 91: 881-888.
15. Mitnick CD, McGee B, Peloquin CA. 2009. Tuberculosis pharmacotherapy: Strategies to optimize patient care. Expert Opin. Pharmacother. 10: 381-401.
16. van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, van Balen GP, Gillespie SH, Boeree MJ. 2011. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin. Infect. Dis. 52:e194-e199.